Type 2 Diabetes Pathophysiology: From Insulin Resistance to β-Cell Failure

Type 2 diabetes (T2D) is a progressive metabolic disorder driven by two core defects: insulin resistance in liver, muscle, and adipose tissue, and pancreatic β-cell dysfunction leading to relative insulin deficiency.

Pathogenic Sequence

  1. Insulin Resistance: Impaired insulin signaling (PI3K/Akt pathway) → reduced GLUT4 translocation in muscle/adipose → decreased glucose uptake; hepatic insulin resistance → unrestrained gluconeogenesis → fasting hyperglycemia.
  2. Compensatory Hyperinsulinemia: β-cells increase insulin output to maintain normoglycemia. This phase can last years.
  3. β-Cell Decompensation: Glucotoxicity, lipotoxicity, amyloid deposition (IAPP), ER stress, and oxidative damage cause β-cell apoptosis and functional decline. Insulin secretion becomes insufficient relative to demand.
  4. Overt Hyperglycemia: Fasting glucose ≥126 mg/dL, HbA1c ≥6.5%, or random ≥200 mg/dL with symptoms.

Key Risk Factors

  • Age ≥45, family history, overweight/obesity (especially visceral), physical inactivity.
  • Hypertension, dyslipidemia (low HDL, high TG), NAFLD, PCOS.
  • Gestational diabetes history, prediabetes (IFG/IGT), certain ethnicities (South Asian, Black, Hispanic, Native American).

Clinical Consequences of Chronic Hyperglycemia

  • Microvascular: Retinopathy, nephropathy, neuropathy.
  • Macrovascular: ASCVD (MI, stroke, PAD) — 2–4× risk.
  • Other: Infection susceptibility, poor wound healing, cognitive decline, hearing loss.

Management Pillars

  • Lifestyle: Mediterranean/DASH diet, 150 min/week moderate activity, 5–10% weight loss if overweight.
  • Metformin first-line (unless contraindicated); add GLP-1 RA or SGLT2i for cardiorenal benefit.
  • Individualized HbA1c targets; avoid therapeutic inertia.
  • Screen for complications annually (eyes, feet, kidneys, lipids, BP).

Early intervention preserves β-cell function and prevents irreversible complications.

Diabetes - Related Articles